Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 12/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11717909 | 0.87 | HTT (0.56) | CCR5HTTHCRTR1HCRTR2LMNA | |
| SCHEMBL3841444 | 0.84 | CCR5 (0.61) | CCR5KCNH2 | |
| SCHEMBL4159647 | 0.83 | LMNA (0.61) | CCR5HTTLMNAHPGDALDH1A1 | |
| SCHEMBL21163104 | 0.81 | HPGD (0.62) | HTTLMNAHPGDALDH1A1CYP2C19 | |
| SCHEMBL1929985 | 0.81 | HTT (0.70) | HTTHPGDALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL411860 | 0.79 | CCR5 (0.50) | CCR5KCNH2KDM4E | |
| SCHEMBL7446407 | 0.79 | HPGD (0.69) | CCR5HTTLMNAHPGDALDH1A1 | |
| SCHEMBL1777672 | 0.79 | LMNA (0.71) | HTTLMNAHPGDALDH1A1CYP2C9 | |
| Ethylene SCHEMBL8379177 | 0.78 | HTT (0.66) | HTTHPGDALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL597286 | 0.78 | GAA (0.57) | CCR5HTTHCRTR1HCRTR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| EP-2059515-A2 | PYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE CCR5 RECEPTORS | Pfizer Limited (GB) | 2009-05-20 | — | — | EP | disclosed |
| US-20090124636-A1 | CHEMICAL COMPOUNDS | PFIZER INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090124636-A1 | CHEMICAL COMPOUNDS | PFIZER INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090124636-A1 | CHEMICAL COMPOUNDS | PFIZER INC. | 2009-05-14 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| WO-2007116313-A2 | PYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE CCR5 RECEPTORS | PFIZER LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007116313-A2 | PYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE CCR5 RECEPTORS | PFIZER LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
| EP-1716156-A2 | CHEMOKINE CCR5 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005075484-A2 | CHEMOKINE CCR5 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-18 | — | — | WO | disclosed |
| US-20050176703-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2005-08-11 | — | — | US | disclosed |
| US-4499100-A | CARDIOUVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124636-A1 | CHEMICAL COMPOUNDS | CCR5, CXCR3, CX3CR1 | CCR5 1/4885HTT 3203/4885HCRTR1 252/4885 |
| US-20080139544-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | CCR5 1/4885HTT 4269/4885HCRTR1 227/4885 |
| US-20050176703-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | CCR5 1/4885HTT 4269/4885HCRTR1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.